Enlivex Therapeutics Ltd..
ENLV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company, developing allogeneic cell therapies for life-threatening inflammatory and immune conditions. Its primary product candidate is Allocetra, an off-the-shelf cell therapy designed to modulate the immune system and promote homeostasis....Show More
Better Health for All
30
Enlivex's entire business is devoted to developing investigational therapies for life-threatening and debilitating conditions, such as sepsis and osteoarthritis, demonstrating a core focus on health improvement.
1
Early Phase IIa data for Allocetra™ in knee osteoarthritis showed a substantial reduction in pain and improvement in function in patients aged 60+ (80-99% improvement over placebo).
2
Over 150 patients have been treated with Allocetra™ in clinical trials with no reported serious adverse events or safety signals attributed to the treatment, indicating a perfect safety record to date.
3
The company describes Allocetra™ as a cost-effective cell therapy with a competitive pharmacoeconomic model.
4
Clinical trials for Allocetra™ include patients aged 18-90 and focus on debilitating and life-threatening conditions, including older adults with osteoarthritis and adult sepsis patients.
5
The company has a policy for evaluating access to investigational agents outside of clinical trials, requiring a positive benefit-risk ratio and consideration for ongoing trials.
6
Enlivex is a clinical-stage company developing Allocetra™, a novel therapeutic modality designed to restore macrophage homeostasis and promote disease resolution.
7
The company conducts clinical studies to safeguard the welfare of subjects and ensure scientific integrity, with trials registered on ClinicalTrials.gov, including double-blind and randomized designs.
8
Fair Money & Economic Opportunity
0
No evidence available to assess Enlivex Therapeutics Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, concrete data points were found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. The articles primarily focus on executive compensation and ownership details, such as CEO Oren Hershkovitz's compensation of US$295.60k, but do not provide information on broader employee compensation, benefits, working conditions, or other metrics required for scoring.
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess Enlivex Therapeutics Ltd. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess Enlivex Therapeutics Ltd. on Honest & Fair Business.
Kind to Animals
0
Enlivex Therapeutics Ltd. conducts pre-clinical studies of its drugs on animals to assess product safety.
1
Specifically, Allocetra was tested in a murine cecal ligation and puncture (CLP) animal model of severe sepsis, which demonstrated a 90% reduction in mortality.
2
No other information regarding animal welfare, testing policies, or alternative methods is provided in the articles.
No War, No Weapons
0
The company's core business is described as a clinical-stage immunotherapy company developing allogeneic cell therapies for life-threatening inflammatory and immune conditions.
1
The provided articles focus on clinical trial results, corporate governance, and investor relations. There is no evidence in any of the articles to suggest any involvement with arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, or any other conflict-related activities or investments. Therefore, all KPIs related to defense or war are not applicable to the company's core operations.
Planet-Friendly Business
0
No specific, concrete evidence was found in the provided articles regarding Enlivex Therapeutics Ltd.'s environmental impact, sustainability practices, or any other metrics related to the 'Planet-Friendly Business' value.
1
The articles either discuss general industry trends in pharmaceutical sustainability,
2
focus on the company's financial and regulatory activities,
3
or detail the sustainability efforts of other companies,
4
without providing specific data for Enlivex Therapeutics Ltd.
5
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Enlivex Therapeutics Ltd.'s respect for cultures and communities. The articles focused on employee numbers
1
, internal codes of conduct
2
, disclosure policies
3
, and access to investigational therapies
4
, none of which contained information relevant to community engagement, cultural impact assessments, local investment, or related metrics.
Safe & Smart Tech
10
Enlivex Therapeutics Ltd. has not reported any data breaches, as confirmed by articles from February 2025.
1
The company has implemented GDPR controls as a baseline standard globally and complies with CCPA/CalOPPA.
2
Its privacy policy, updated July 3rd, 2024, states that personal data should only be collected for a specific purpose and used only for that purpose, with conversation and personal data stored for up to 6 years, and disposed of within 60 days after account deletion.
3
The company also states it does not sell the personal information of its users.
4
Users are provided with comprehensive rights to access, update, retrieve, and delete personal data, with a self-service setup and a one-month response time for requests.
5
Enlivex is subject to various laws and regulations, including the Securities Act, Securities Exchange Act, Federal Food, Drug, and Cosmetic Act, fair competition and antitrust laws, and the U.S. Foreign Corrupt Practices Act.
6
Zero Waste & Sustainable Products
0
No evidence available to assess Enlivex Therapeutics Ltd. on Zero Waste & Sustainable Products.